Development of a microdosimetry-based method to derive cell survival rates for evaluating the biological effects of BNCT

Boron neutron capture therapy (BNCT) dose calculation often relies on fixed relative biological effectiveness (RBE) and compound biological effectiveness (CBE) values, despite their dependence on beam quality and tumor biology. We developed a microdosimetry-driven framework that predicts cell survival and RBE for BNCT by coupling PHITS lineal energy (T-SED) calculations with the microdosimetric kinetic (MK) model. MK parameters (<i>α</i><sub>0</sub>,<i>β</i>,<i>r</i><sub><i>d</i></sub>,<i>y</i><sub>0</sub>) were derived for BNCT relevant cell lines (U87 glioblastoma, NB1RG skin fibroblasts, SAS human squamous carcinoma, and SCC7 murine squamous carcinoma) using low-LET reference datasets curated in the PIDE database and irradiation conditions reproduced in PHITS. The derived parameters successfully reproduced<i>in vitro</i>survival curves for various charged particles across different energies, and when applied to neutron fields representative of BNCT systems (Kyoto University Reactor thermal neutron beam, cyclotron-based epithermal neutron source using a beryllium target, and linear accelerator system using a lithium target), the framework also reproduced measured<i>in vitro</i>data. Predicted RBE at 10% survival (RBE<sub>10</sub>) agreed with measurements across cell lines and beam qualities, with only a slight deviation for SCC7 under the CICS spectrum and moderate deviations for SAS due to limited and heterogeneous low-LET datasets in PIDE. This method enables spectrum and cell-line specific estimation of biological effect, supporting replacement of fixed RBE/CBE with spectrum aware quantities to improve BNCT dose prescription and safety. The framework can also guide neutron-beam design by providing preliminary RBE estimates prior to construction of the moderator and beam shaping assembly. Incorporating intracellular boron microdistribution in future work is expected to refine CBE estimates and enhance biological accuracy in BNCT treatment planning. This framework provides a physics-based alternative to fixed RBE/CBE values.

Authors

Institutions

Publication Details

Journal
Biomedical Physics & Engineering Express
Published
2026-02-11
DOI
https://doi.org/10.1088/2057-1976/ae44a2
Primary Topic
Boron Compounds in Chemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of a microdosimetry-based method to derive cell survival rates for evaluating the biological effects of BNCT

Naonori Hu, Mai Nojiri, Takushi Takata, Liang Zhao et al.
Biomedical Physics & Engineering Express
Boron Compounds in Chemistry
article

Development of a microdosimetry-based method to derive cell survival rates for evaluating the biological effects of BNCT

Naonori Hu, Mai Nojiri, Takushi Takata, Liang Zhao, Ryusuke Yamazaki, Hiroki Tanaka
article en

Abstract

Boron neutron capture therapy (BNCT) dose calculation often relies on fixed relative biological effectiveness (RBE) and compound biological effectiveness (CBE) values, despite their dependence on beam quality and tumor biology. We developed a microdosimetry-driven framework that predicts cell survival and RBE for BNCT by coupling PHITS lineal energy (T-SED) calculations with the microdosimetric kinetic (MK) model. MK parameters (<i>α</i><sub>0</sub>,<i>β</i>,<i>r</i><sub><i>d</i></sub>,<i>y</i><sub>0</sub>) were derived for BNCT relevant cell lines (U87 glioblastoma, NB1RG skin fibroblasts, SAS human squamous carcinoma, and SCC7 murine squamous carcinoma) using low-LET reference datasets curated in the PIDE database and irradiation conditions reproduced in PHITS. The derived parameters successfully reproduced<i>in vitro</i>survival curves for various charged particles across different energies, and when applied to neutron fields representative of BNCT systems (Kyoto University Reactor thermal neutron beam, cyclotron-based epithermal neutron source using a beryllium target, and linear accelerator system using a lithium target), the framework also reproduced measured<i>in vitro</i>data. Predicted RBE at 10% survival (RBE<sub>10</sub>) agreed with measurements across cell lines and beam qualities, with only a slight deviation for SCC7 under the CICS spectrum and moderate deviations for SAS due to limited and heterogeneous low-LET datasets in PIDE. This method enables spectrum and cell-line specific estimation of biological effect, supporting replacement of fixed RBE/CBE with spectrum aware quantities to improve BNCT dose prescription and safety. The framework can also guide neutron-beam design by providing preliminary RBE estimates prior to construction of the moderator and beam shaping assembly. Incorporating intracellular boron microdistribution in future work is expected to refine CBE estimates and enhance biological accuracy in BNCT treatment planning. This framework provides a physics-based alternative to fixed RBE/CBE values.

Biomedical Physics & Engineering ExpressVol. 12(2)
Kyoto University (JP), Osaka University of Pharmaceutical Sciences (JP)
Openalex Percentile: Top 59%
Boron Compounds in Chemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.